S2Medical AB (publ)
STO:S2M
Net Margin
S2Medical AB (publ)
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | Company | Market Cap |
Net Margin |
||
---|---|---|---|---|---|
SE |
S
|
S2Medical AB (publ)
STO:S2M
|
12m SEK |
39%
|
|
CH |
![]() |
Alcon AG
SIX:ALC
|
36B CHF |
11%
|
|
JP |
![]() |
Hoya Corp
TSE:7741
|
6.6T JPY |
23%
|
|
DK |
![]() |
Coloplast A/S
CSE:COLO B
|
139.3B DKK |
16%
|
|
US |
![]() |
Align Technology Inc
NASDAQ:ALGN
|
15B USD |
10%
|
|
CH |
![]() |
Ypsomed Holding AG
SIX:YPSN
|
5.9B CHF |
12%
|
|
UK |
![]() |
ConvaTec Group PLC
LSE:CTEC
|
4.9B GBP |
8%
|
|
CN |
![]() |
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
44.9B CNY |
40%
|
|
US |
![]() |
Merit Medical Systems Inc
NASDAQ:MMSI
|
5B USD |
9%
|
|
CA |
![]() |
Bausch + Lomb Corp
NYSE:BLCO
|
5.1B USD |
-8%
|
|
US |
![]() |
Lantheus Holdings Inc
NASDAQ:LNTH
|
5B USD |
17%
|
S2Medical AB (publ)
Glance View
S2Medical AB engages in research and development in biotechnology. The company is headquartered in Linkoping, Ostergotland. The company went IPO on 2018-11-28. The firm focuses on developing products for healing burns and chronic wounds, from debridement and granulation to reepithelialization. The firm's product portfolio includes INSTAQRETT, a sterile single-use mechanical debridement tool, the Epiprotect product line based on its collagen-mimicking Eiratex material, which includes EPIPROTECT Safestop, a blood-stilling membrane dressing, EPIPROTECT 2117, a synthetic substitute to allografts and xenografts, EPIPROTECT ULCER, dressing for treating ulcers, as well as INSTABIND bandages and Instagraft, a single-use medical device designed to treat chronic wounds with microtransplants from the patient's own skin without creating any new wounds. The firm is also the official distributor of Silverlon antimicrobial dressings for Nordic countries. In addition, it operates the S2Clinic, a wound healing center in Sweden.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on S2Medical AB (publ)'s most recent financial statements, the company has Net Margin of 38.7%.